Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban-based versus antiplatelet-based antithrombotic strategy after TAVR
NL-OMON45994Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban, clopidogrel and aspirin in aortic stenosis (AS) (2 arms), sponsored by Bayer. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Dec 2015; status: active, not recruiting.
02
Drugs
rivaroxabanclopidogrelaspirin
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on NL-OMON45994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45994.